Horizon Therapeutics plc: New Real-World Analysis of TEPEZZA (teprotumumab-trbw) Use Indicates a Small Percentage of People Receive a Second Course of Treatment
-- Analysis presented at American Thyroid Association Annual Meeting (ATA 2022) shows during a two-year period, 4.9% of patients who completed a full course of TEPEZZA were later prescribed a second